Daiichi Sankyo to pay $132.5 million to acquire IP rights for anti-TAMUC1 antibody in DS-3939 from Glycotope: Tokyo Wednesday, January 15, 2025, 09:00 Hrs [IST] Daiichi Sankyo Com ...

Our life is full of initials and codes. There is not a day that you do not interact with a code of some sort like a bar code or a ...

(Novartis) is pleased to announce that eligible patients in Ontario now have access to Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan injection), a targeted radioligand therapy for adult patients ...